Kymab announced its clinical trial agreement with F. Hoffmann-La Roche Ltd under which Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination with Kymab’s lead investigational anti-ICOS antibody therapy KY1044 in Kymab’s upcoming Phase I/II clinical studies in patients with advanced solid cancers.
Kymab will be responsible for conducting the clinical trials, and both companies will share data from the trials. Kymab continues to retain all commercial rights to KY1044. KY1044 is designed to both deplete intratumoral Regulatory T-cells and stimulate T Effector cells to enhance the immune response against tumors.
Kymab plans to conduct a Phase I/II study in a variety of solid tumours both as monotherapy and in combination with atezolizumab. Indications that have elevated levels of both ICOS and FOXP3 might be especially responsive to this combination of checkpoint inhibitors.
Kymab will lead studies to evaluate this hypothesis: atezolizumab, an anti-PD-L1 antibody that acts as a checkpoint inhibitor, and KY1044, an antibody targeting ICOS expression, will be tested for synergistic action to recalibrate the immune response. Kymab plans to initiate monotherapy studies of KY1044 in the first half of 2019 and studies in combination with TECENTRIQ in the second half.
Based in Cambridge, UK, Kymab Limited discovers, develops, and commercializes human therapeutic monoclonal antibodies for the treatment of human diseases using its proprietary Kymouse platform. Its platform captures the diversity of the B lymphocyte component of the human immune system and generates human antibody-based biopharmaceuticals directed against clinically precedented drug targets and drugs against novel targets.